Holen Sie sich die Stockscreener-App
2.53
0.00%
0.00
Schlusskurs vom Vortag:
$2.53
Offen:
$2.53
24-Stunden-Volumen:
749.79K
Relative Volume:
0.99
Marktkapitalisierung:
$73.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.52M
KGV:
-0.9731
EPS:
-2.6
Netto-Cashflow:
$-56.92M
1W Leistung:
+0.00%
1M Leistung:
-4.89%
6M Leistung:
+73.29%
1J Leistung:
-86.43%
1-Tages-Spanne:
$2.45
$2.64
1-Wochen-Bereich:
$2.45
$2.64
52-Wochen-Spanne:
$1.25
$32.41
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
Firmenname
Aerovate Therapeutics Inc
Sektor
Branche
Telefon
617-443-2400
Adresse
930 WINTER STREET, WALTHAM
Vergleichen Sie AVTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTE
Aerovate Therapeutics Inc
|
2.53 | 73.14M | 0 | -75.52M | -56.92M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-06-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-03-25 | Fortgesetzt | Jefferies | Buy |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-12-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-08-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-07-26 | Eingeleitet | Cowen | Outperform |
| 2021-07-26 | Eingeleitet | Evercore ISI | Outperform |
| 2021-07-26 | Eingeleitet | Jefferies | Buy |
| 2021-07-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Aerovate Therapeutics Inc Aktie (AVTE) Neueste Nachrichten
STOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate MergerAVTE, BCOV, ALVR, AE - cnhinews.com
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update - Defense World
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Down 5.3% in November - MarketBeat
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc.AVTE - The Eastern Progress Online
Verition Fund Management LLC Sells 149,137 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Pulmonary Arterial Hypertension Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novartis, Insmed Inc, Chugai Pharma, Merck Sharp & Dohme, Janssen Pharma, Aerovate - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, PFIE, EMKR on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE an - GuruFocus.com
GSA Capital Partners LLP Has $865,000 Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - MarketBeat
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 17.3% - MarketBeat
Wedbush Research Analysts Raise Earnings Estimates for AVTE - Defense World
What is Wedbush's Forecast for AVTE FY2024 Earnings? - MarketBeat
Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift - TipRanks
Finansavisen - Finansavisen
Jade Biosciences’ Merger with Aerovate Therapeutics - Global Legal Chronicle
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, STAF, AVTE on Behalf of Shareholders - Marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Air Transport Services Group, Inc. (Nasdaq– ATSG), Micropac Industries, Inc. (OTC – MPAD), Aerovate Therapeutics, Inc. (Nasdaq – AVTE), Outbrain Inc. (Nasd - ForexTV.com
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Marketscreener.com
Aerovate Therapeutics Enters into Merger Agreement with Jade Biosciences - Defense World
How Fairmount’s Paragon incubator steered two more companies to NASDAQ - BioCentury
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - Marketscreener.com
Kuehn Law Encourages OB, AVTE, B, and MNTX Investors to Contact Law Firm - The Malaysian Reserve
SEC Form 425 filed by Aerovate Therapeutics Inc. - Quantisnow
Form 425 Aerovate Therapeutics, Filed by: Aerovate Therapeutics, Inc. - StreetInsider.com
Aerovate (AVTE) Shares Rally As Market Responds To A Merger Agreement - Stocks Telegraph
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
Jade Biosciences and Aerovate announce merger deal - Investing.com
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment - MarketWatch
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Aerovate climbs on all-stock merger deal with Jade - MSN
Aerovate stock rises on all-stock merger deal (AVTE:NASDAQ) - Seeking Alpha
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement - GlobeNewswire
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Down 21.4% in October - MarketBeat
Aerovate Therapeutics regains Nasdaq compliance - Investing.com India
Aerovate Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Cubist Systematic Strategies LLC Makes New Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Analyzing Aerovate Therapeutics Inc (AVTE) After Recent Trading Activity - Knox Daily
Aerovate Therapeutics announces board member resignation - Investing.com India
Aerovate Therapeutics announces board member resignation By Investing.com - Investing.com UK
Aerovate Therapeutics Board Member Maha Katabi Resigns - TipRanks
XTX Topco Ltd Invests $35,000 in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Finanzdaten der Aerovate Therapeutics Inc-Aktie (AVTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aerovate Therapeutics Inc-Aktie (AVTE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dake Benjamin T | SEE REMARKS |
Aug 01 '24 |
Option Exercise |
1.74 |
1,507 |
2,622 |
14,252 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 17 '24 |
Buy |
1.67 |
928,110 |
1,549,944 |
7,893,678 |
| Eldridge George A | SEE REMARKS |
Jun 14 '24 |
Option Exercise |
2.14 |
15,000 |
32,100 |
20,022 |
| Eldridge George A | SEE REMARKS |
Jun 14 '24 |
Sale |
25.03 |
15,000 |
375,450 |
5,022 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER |
Jun 14 '24 |
Option Exercise |
14.59 |
10,600 |
154,654 |
10,600 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER |
Jun 14 '24 |
Sale |
25.00 |
10,600 |
265,000 |
0 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
Jun 13 '24 |
Option Exercise |
2.14 |
6,000 |
12,840 |
11,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
Jun 13 '24 |
Sale |
24.50 |
6,000 |
147,000 |
5,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
May 17 '24 |
Option Exercise |
2.14 |
4,000 |
8,560 |
9,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
May 17 '24 |
Sale |
21.08 |
4,000 |
84,332 |
5,602 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):